Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience.
作者信息
Hoffman-Censits Jean, Choi Woonyoung, Bivalacqua Trinity J, Pierorazio Philip, Kates Max, Lombardo Kara, Parini Vamsi, McConkey David, Trabulsi Edouard J, Hahn Noah, Matoso Andres
机构信息
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
The James Buchanan Brady Urological Institute and Department of Urology, Baltimore, MD.
出版信息
Clin Genitourin Cancer. 2021 Apr;19(2):176-181. doi: 10.1016/j.clgc.2020.10.009. Epub 2020 Nov 12.
Abstract
摘要
相似文献
1
Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience.小细胞膀胱癌对二线及后续检查点抑制剂治疗的反应：回顾性经验
Clin Genitourin Cancer. 2021 Apr;19(2):176-181. doi: 10.1016/j.clgc.2020.10.009. Epub 2020 Nov 12.
2
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.PD-1/PD-L1 免疫疗法治疗膀胱癌的研究进展：未来已来。
Cancer Treat Rev. 2017 Mar;54:58-67. doi: 10.1016/j.ctrv.2017.01.007. Epub 2017 Feb 2.
3
Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.尿路上皮癌的免疫治疗，第1部分：晚期或转移性疾病中的T细胞检查点抑制
Clin Adv Hematol Oncol. 2017 Jun;15(6):466-477.
4
Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.检查点抑制剂：治疗尿路上皮膀胱癌的新模式。
Med Oncol. 2017 Sep 1;34(10):170. doi: 10.1007/s12032-017-1029-8.
5
Immunotherapy Advances in Urothelial Carcinoma.免疫治疗在尿路上皮癌中的进展。
Curr Treat Options Oncol. 2018 Dec 15;19(12):79. doi: 10.1007/s11864-018-0598-x.
6
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.尿路上皮癌的免疫治疗：当前证据与未来方向
Curr Urol Rep. 2018 Nov 7;19(12):109. doi: 10.1007/s11934-018-0851-7.
7
Checkpoint inhibitors in BCG-unresponsive nonmuscle invasive bladder cancer: can they help spare the bladder?卡介苗无反应性非肌肉浸润性膀胱癌中的检查点抑制剂：它们能帮助保留膀胱吗？
Immunotherapy. 2021 Sep;13(13):1105-1111. doi: 10.2217/imt-2021-0030. Epub 2021 Jun 29.
8
Immunotherapy: The Wave of the Future in Bladder Cancer?免疫疗法：膀胱癌治疗的未来潮流？
Clin Genitourin Cancer. 2017 Jun;15(3S):S3-S17. doi: 10.1016/j.clgc.2017.05.025.
9
[Immunotherapy for Bladder Cancer].[膀胱癌的免疫疗法]
Klin Onkol. 2017 Winter;30(Supplementum3):6-9. doi: 10.14735/amko20173S6.
10
Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.免疫疗法在晚期尿路上皮癌中的新作用。
Curr Oncol Rep. 2018 Apr 11;20(6):48. doi: 10.1007/s11912-018-0693-y.
引用本文的文献
1
Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of Neuroendocrine Bladder Cancer.神经内分泌膀胱癌的分子特征、异质性、可塑性及起源细胞
Cancer Heterog Plast. 2025;2(1). doi: 10.47248/chp2502010005. Epub 2025 Mar 6.
2
Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management.膀胱小细胞癌：发病机制、临床表现及治疗综述
Bladder Cancer. 2025 Aug 18;11(3):23523735251370956. doi: 10.1177/23523735251370956. eCollection 2025 Jul-Sep.
3
A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)-design and rationale.一项关于鲁比卡丁联合或不联合阿维鲁单抗治疗膀胱小细胞癌（LASER）的II期研究——设计与原理
Future Oncol. 2025 Apr;21(10):1171-1177. doi: 10.1080/14796694.2025.2480534. Epub 2025 Mar 21.
4
Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives.转移性尿路上皮癌一线治疗的不断演变格局：当前见解与未来展望
Cancers (Basel). 2024 Dec 5;16(23):4078. doi: 10.3390/cancers16234078.
5
PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers.PD-1 阻断联合顺铂为基础的化疗治疗小细胞/神经内分泌膀胱癌和前列腺癌患者。
Cell Rep Med. 2024 Nov 19;5(11):101824. doi: 10.1016/j.xcrm.2024.101824. Epub 2024 Nov 12.
6
Treatment and survival of non-metastatic small cell carcinoma of the bladder from multiple centers in China.中国多中心非转移性小细胞膀胱癌的治疗与生存。
Sci Rep. 2024 Oct 20;14(1):24652. doi: 10.1038/s41598-024-75512-z.
7
Molecular profile of bladder cancer progression to clinically aggressive subtypes.膀胱癌向临床侵袭性亚型进展的分子特征。
Nat Rev Urol. 2024 Jul;21(7):391-405. doi: 10.1038/s41585-023-00847-7. Epub 2024 Feb 6.
8
An Unexpected and Unpredictable Emergence of Muscle-Invasive Bladder Cancer in a Patient Successfully Treated With Nivolumab for Small-Cell Bladder Cancer.一名接受纳武单抗成功治疗小细胞膀胱癌的患者意外且不可预测地出现了肌层浸润性膀胱癌。
Cureus. 2022 Dec 6;14(12):e32244. doi: 10.7759/cureus.32244. eCollection 2022 Dec.
本文引用的文献
1
Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.具有小细胞组织学特征的尿路上皮癌具有明确的高肿瘤突变负担、频繁的 TP53 和 RB 突变以及独特的基因表达谱。
Eur Urol Oncol. 2021 Apr;4(2):297-300. doi: 10.1016/j.euo.2019.12.002. Epub 2020 Feb 13.
2
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.PURE-01的更新结果：新辅助派姆单抗在组织学变异的肌层浸润性膀胱癌患者中的初步活性
Eur Urol. 2020 Apr;77(4):439-446. doi: 10.1016/j.eururo.2019.10.026. Epub 2019 Nov 8.
3
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合铂类依托泊苷与铂类依托泊苷一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
4
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.癌症基因组图谱表达亚型分析在晚期尿路上皮癌中对检查点抑制的反应，并确定一组具有高生存概率的患者亚群。
Eur Urol. 2019 Jun;75(6):961-964. doi: 10.1016/j.eururo.2019.02.017. Epub 2019 Mar 7.
5
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌。
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
6
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.多中心前瞻性 II 期试验：新辅助剂量密集型吉西他滨联合顺铂治疗肌层浸润性膀胱癌。
J Clin Oncol. 2018 Jul 1;36(19):1949-1956. doi: 10.1200/JCO.2017.75.0158. Epub 2018 May 9.
7
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.膀胱和肺的小细胞癌具有趋同但不同的发病机制。
Clin Cancer Res. 2018 Apr 15;24(8):1965-1973. doi: 10.1158/1078-0432.CCR-17-2655. Epub 2017 Nov 27.
8
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.肌层浸润性膀胱癌的综合分子特征分析
Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5.
9
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.一线帕博利珠单抗治疗铂类药物治疗禁忌的局部晚期和不可切除或转移性尿路上皮癌患者（KEYNOTE-052）：一项多中心、单臂、2 期研究。
Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.
10
Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.通过液体活检分析监测晚期膀胱癌的治疗反应和转移复发。
Eur Urol. 2018 Apr;73(4):535-540. doi: 10.1016/j.eururo.2017.09.011. Epub 2017 Sep 27.
Zotero 插件